Thymic stromal lymphopoietin (TSLP) is recently implicated as a key molecule for initiating allergic inflammation at the epithelial cell-dendritic cell (DC) interface. TSLP is produced predominantly by epithelial cells, and induces the production of multiple chemokines and cytokines by several innate cell types such as DCs, mast cells, eosinophils, and NKT cells, contributing to the innate phase of allergic inflammation. However, its function is more prominent in the DC-mediated adaptive phase of allergic inflammation. TSLP-activated myeloid DCs (mDCs) can promote naïve CD4 + T cells to differentiate into a Th2 phenotype. We analyzed the signal transduction mechanisms of TSLP in human primary mDCs and found that it potently transduces a unique Th2-inducing compound signal in DCs. Whereas activation of nuclear factor B (predominantly p50) drives DCs to produce OX40L to induce Th2 differentiation, the activation of signal transducer and activator of transcription 6 (STAT6) triggers DCs to secrete chemokines necessary for the recruitment of Th2 cells. In addition, TSLP signaling limits the activation of STAT4 and interferon regulatory factor 8 (IRF8), which are essential factors for the production of the Th1-polarizing cytokine interleukin-12. Because TSLP can be a rational therapeutic target for the treatment of allergic disorders, elucidating the mechanisms that regulate TSLP expression and the effects of TSLP on orchestrating the immune response toward a Th2 phenotype is essential for developing anti-TSLP therapy.
Introduction
The actin blot is shown as a loading control.
(C) mDCs transfected with small interference RNA (siRNA) were stimulated with poly(I:C) for 24 h and the concentration of IL-12p40 in the culture supernatants and the mean fluorescent intensity of cell-surface CD80, one of the DC activation markers, are depicted. Knocking down IRF8 or STAT4 deeply affects IL-12 production but not induction of CD80. Since TSLP-DCs do not upregulate the abundance of IRF8 and STAT4, they are
